Many studies have been conducted to evaluate curcumin’s potential in patients with IBD for its efficacy as an anti-inflammatory without significant side effects [29–32]. McCann et al., found different turmeric extracts could benefit the variants of SLC22A4 and IL-10 associated with IBD, by reducing inappropriate epithelial cell transport (SLC22A4, 503F) and increasing anti-inflammatory cytokine gene promoter activity (IL-10, -1082A) [33]. Beloqui et al., designed a local delivery of curcumin using pH-sensitive polymeric nanoparticles and found it significantly decreased neutrophil infiltration and TNF-α secretion [34]. curcumin is considered as an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers